Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes

Atherosclerosis

Volumn 189, Issue 1, 2006, Pages 236-240

  Krzyzanowska, Katarzyna ^a   Mittermayer, Friedrich ^b   Krugluger, Walter ^a   Schnack, Christoph ^a   Hofer, Martin ^a   Wolzt, Michael ^b   Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Asymmetric dimethylarginine; Homocysteine; Macrovascular disease; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ARGININE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORRELATION COEFFICIENT; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; EVALUATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; STROKE;

AGED; ARGININE; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33748982539     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.12.007     Document Type: Article

References (28)

1. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
2. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
3. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
4. Hörl W.H. Atherosclerosis and uremia: significance of non-traditional risk factors. Wien Klin Wochenschr 115 (2003) 220-234
5. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
6. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
7. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
8. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
9. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
10. Coull B.M., Malinow M.R., Beamer N., et al. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 21 (1990) 572-576
11. Perry I.J., Refsum H., Morris R.W., et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346 (1995) 1395-1398
12. Hoogeveen E.K., Kostense P.J., Jager A., et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 54 (1998) 203-209
13. De Bree A., Verschuren W.M., Kromhout D., Kluijtmans L.A., and Blom H.J. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 54 (2002) 599-618
14. Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease. Clin Chem 44 (1998) 1833-1843
15. D'Angelo A., and Selhub J. Homocysteine and thrombotic disease. Blood 90 (1997) 1-11
16. Araki A., Hosoi T., Orimo H., and Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism 54 (2005) 809-814
17. Stühlinger M.C., Tsao P.S., Her J.H., et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104 (2001) 2569-2575
18. Böger R.H., Lentz S.R., Bode-Böger S.M., Knapp H.R., and Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 100 (2001) 161-167
19. Wanby P., Brattstrom L., Brudin L., Hultberg B., and Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest 63 (2003) 347-353
20. Ziegler S., Mittermayer F., Plank C., et al. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 90 (2005) 2175-2178
21. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
22. Teerlink T., Nijveldt R.J., de Jong S., and van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
23. Mittermayer F., Namiranian K., Pleiner J., Schaller G., and Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond) 106 (2004) 577-581
24. Nanayakkara P.W., Teerlink T., Stehouwer C.D., et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 68 (2005) 2230-2236
25. Suda O., Tsutsui M., Morishita T., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of rennin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24 (2004) 1682-1688
26. McQuillan B.M., Beilby J.P., Nidorf M., Thompson P.L., and Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 99 (1999) 2383-2388
27. Wilson K.M., and Lentz S.R. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med 5 (2005) 163-171
28. Wollesen F., Brattstrom L., Refsum H., et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55 (1999) 1028-1035